Total Payments
$1.4M
2024 Payments
$240,238
Companies
38
Transactions
949
Medicare Patients
154
Medicare Billing
$8,976
Payment Breakdown by Category
Other$646,349 (46.9%)
Consulting$604,807 (43.8%)
Travel$102,016 (7.4%)
Food & Beverage$21,626 (1.6%)
Research$4,500 (0.3%)
Education$109.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $604,807 | 151 | 43.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $464,211 | 137 | 33.7% |
| Travel and Lodging | $102,016 | 255 | 7.4% |
| Honoraria | $72,099 | 29 | 5.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $63,340 | 23 | 4.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $46,700 | 18 | 3.4% |
| Food and Beverage | $21,626 | 331 | 1.6% |
| Unspecified | $4,500 | 1 | 0.3% |
| Education | $109.40 | 4 | 0.0% |
Payments by Type
General
$1.4M
948 transactions
Research
$4,500
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $426,387 | 361 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $348,052 | 182 | $0 (2024) |
| ABBVIE INC. | $101,037 | 128 | $0 (2022) |
| Novo Nordisk Inc | $72,829 | 33 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $60,802 | 22 | $0 (2024) |
| GlaxoSmithKline, LLC. | $57,097 | 33 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $53,415 | 17 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $46,113 | 36 | $0 (2024) |
| Mirum Pharmaceuticals, Inc. | $28,985 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $23,054 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $240,238 | 150 | Gilead Sciences, Inc. ($35,563) |
| 2023 | $234,865 | 106 | INTERCEPT PHARMACEUTICALS, INC. ($67,907) |
| 2022 | $159,947 | 102 | Gilead Sciences, Inc. ($45,618) |
| 2021 | $109,612 | 76 | Intercept Pharmaceuticals, Inc. ($54,037) |
| 2020 | $171,312 | 78 | Intercept Pharmaceuticals, Inc. ($102,189) |
| 2019 | $155,248 | 123 | Gilead Sciences, Inc. ($59,584) |
| 2018 | $137,365 | 125 | Gilead Sciences, Inc. ($99,509) |
| 2017 | $170,820 | 189 | Gilead Sciences Inc ($101,713) |
All Payment Transactions
949 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,615.00 | General |
| 12/17/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,900.00 | General |
| Category: HCV | ||||||
| 12/11/2024 | ORPHALAN INC | CUVRIOR (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Hepatology | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $1,240.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $531.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $115.79 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Honoraria | Cash or cash equivalent | $2,400.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Kowa Research Institute, Inc. | — | Food and Beverage | Cash or cash equivalent | $309.61 | General |
| 12/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.89 | General |
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $1,368.90 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $200.48 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $93.03 | General |
| Category: LIVER DISEASE | ||||||
| 12/01/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: Alagille syndrome | ||||||
| 11/28/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Consulting Fee | Cash or cash equivalent | $5,230.00 | General |
| Category: INFLAM | ||||||
| 11/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $102.43 | General |
| 11/22/2024 | Ipsen Innovation | IQIRVO (Drug) | Consulting Fee | Cash or cash equivalent | $2,490.00 | General |
| Category: Rare Disease | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 11/20/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $98.29 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $288.22 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $49.95 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $45.90 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $45.90 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.16 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2a2b Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Chronic Hepatitis B Infection | Janssen Research & Development, LLC | $4,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 31 | 33 | $3,300 | $825.84 |
| 2022 | 3 | 69 | 76 | $17,201 | $5,741 |
| 2021 | 3 | 41 | 42 | $6,383 | $2,001 |
| 2020 | 1 | 13 | 13 | $1,300 | $407.11 |
Total Patients
154
Total Services
164
Medicare Billing
$8,976
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 91200 | Measurement of liver stiffness | Office | 2023 | 31 | 33 | $3,300 | $825.84 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $9,765 | $3,348 | 34.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 18 | $4,336 | $1,608 | 37.1% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 29 | 31 | $3,100 | $785.96 | 25.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $4,340 | $1,484 | 34.2% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 18 | 19 | $1,900 | $484.48 | 25.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 11 | 11 | $143.00 | $33.00 | 23.1% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2020 | 13 | 13 | $1,300 | $407.11 | 31.3% |
About Dr. Kris Kowdley, MD
Dr. Kris Kowdley, MD is a Gastroenterology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699850404.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kris Kowdley, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $240,238 received in 2024. These payments were reported across 949 transactions from 38 companies. The most common payment nature is "Consulting Fee" ($604,807).
As a Medicare-enrolled provider, Kowdley has provided services to 154 Medicare beneficiaries, totaling 164 services with total Medicare billing of $8,976. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Seattle, WA
- Active Since 10/27/2006
- Last Updated 06/08/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1699850404
Products in Payments
- Epclusa (Drug) $255,869
- OCALIVA (Drug) $183,591
- Mavyret (Drug) $58,720
- Vemlidy (Drug) $50,172
- OCA (Drug) $28,221
- IQIRVO (Drug) $27,424
- Livdelzi (Drug) $25,572
- Livmarli (Drug) $23,615
- REZDIFFRA (Drug) $20,434
- MAVYRET (Drug) $18,212
- Viekira (Drug) $13,555
- XIFAXAN (Drug) $9,361
- TERLIVAZ (Drug) $9,338
- Vosevi (Drug) $7,790
- RDI Research (Device) $4,800
- Harvoni (Drug) $4,503
- Bylvay (Drug) $3,317
- CUVRIOR (Drug) $3,134
- RESMETIROM (Drug) $2,415
- Lenvima (Drug) $1,847
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Seattle
Scott Lee
Gastroenterology — Payments: $252,698
Gastroenterology $252,698
Andrew Ross, Md, MD
Gastroenterology — Payments: $109,536
Gastroenterology $109,536
Dr. Anand Singla, M.d, M.D
Gastroenterology — Payments: $79,123
Gastroenterology $79,123
George Mcdonald
Gastroenterology — Payments: $69,477
Gastroenterology $69,477
Shayan Irani, Md, MD
Gastroenterology — Payments: $58,182
Gastroenterology $58,182
Dr. Adam Templeton, M.d, M.D
Gastroenterology — Payments: $58,097
Gastroenterology $58,097